24 Aug MilliporeSigma projects expand Wisconsin’s biohealth muscle
Wisconsin’s burgeoning biohealth sector continued to grow this summer as MilliporeSigma, a leading international life science business, broke ground on a new facility in Sheboygan and opened an expanded production facility in Verona.
The company’s projects are more evidence of the state’s strength in bioscience and pharmaceuticals.
MilliporeSigma, the U.S. and Canada life science business of Merck KGaA of Darmstadt, Germany, broke ground in July on a lateral flow membrane production facility in Sheboygan.
Supported by a $136.7 million contract award from the U.S. Department of Defense on behalf of the Department of Health and Human Services, the facility will manufacture lateral flow membranes used in manufacturing rapid diagnostic test kits, including for COVID-19.
“This new facility will expand much-needed access of critical raw materials to the world’s most sophisticated diagnostic manufacturers,” said Jean-Charles Wirth, head of science and lab solutions for the life science business of Merck KGaA.
Wisconsin Governor Tony Evers said the facility will promote health and safety while building Wisconsin’s economy.
WEDC authorized up to $200,000 in performance-based state income tax credits for the project over a three-year period. “Wisconsin is proud to have innovative and forward-thinking companies like MilliporeSigma develop here,” said Missy Hughes, WEDC secretary and CEO. “Companies have a choice when deciding to expand, and MilliporeSigma’s decision to invest in Verona is a testament to Wisconsin’s strong business climate and dedicated workforce.”